
Novo Claims Wegovy Reduces BMI and Obesity Rates in Children in Trial
Novo on Monday released full results from an advanced trial showing that its blockbuster Wegovy injection helped children ages 6 to under 12 with obesity lose weight, significantly lowering their body mass index.
Wegovy reduced BMI by about 19.7 percentage points on average compared to a placebo at 68 weeks, with BMI decreasing by 17.4% in children receiving the drug and increasing by 2.2% in those receiving a placebo. These results assumed that patients remained on treatment during the trial.
When evaluating all children in the study, including those who stopped treatment, Wegovy reduced BMI by an estimated average of 16.2 percentage points more than placebo at 68 weeks. The 167 children in the study underwent lifestyle changes throughout the trial, including a low-calorie diet and increased physical activity.
The detailed findings mark an encouraging advance in the treatment of childhood obesity – a chronic disease that can lead to serious cardiovascular, metabolic and psychosocial consequences, but which has few treatment options for young children. If left unchecked, childhood obesity can spread into adulthood, leading to earlier and more serious health complications.
“This is a very significant disease burden in this very young patient population,” said Dr. Andrea Traina, medical director responsible for obesity at Novo.
In 2025, the disease will affect an estimated 177 million children and adolescents aged 5 to 19 worldwide, according to the World Obesity Federation. This figure is expected to reach 228 million by 2040.
Although Wegovy is already approved to treat obesity in children ages 12 and older, there are currently no medications approved for children younger than 12 years old. The latest results prove that Wegovy can potentially fill this treatment gap, safely and effectively reducing disease severity in children as young as 6 years old.
In Novo’s trial, 85% of children started out with moderate to severe obesity, which corresponds to BMI cutoffs of 35 and above and 40 or above, respectively. Nearly half already suffered from at least one obesity-related complication, such as high blood pressure, high cholesterol or sleep apnea.
But more than 40% of children treated with Wegovy were no longer classified as having obesity after 68 weeks of trial, assuming patients remained on treatment. Novo initially shared this finding in September.
“We are working to control this chronic disease in this patient population while they are still so young and at such high risk for more advanced and accelerated disease progression because they developed it so early,” Traina said.
Novo said Wegovy’s overall safety and tolerability in children — how well patients handled the drug — were consistent with those seen in trials with adults. The company added that it has not observed any safety issues related to children’s growth or pubertal development.
However, the two-year study does not establish whether early treatment of obesity can change its long-term trajectory, or what treatment and maintenance might look like as children reach adulthood, Traina said.
“This is something that still has a lack of evidence,” she said, noting the potential for future research.
Gn bussni